Sartorius Stedim Biotech FY25 Profit Rises; Forecasts Continued Growth in FY26

Sartorius Stedim Biotech (EPA: DIM) reported higher full-year 2025 earnings on February 3, 2026, and projected sustained growth for 2026 and beyond, driven by strong demand in biopharmaceutical manufacturing. The company cited robust order intake and expanding capacity utilization across its filtration and fluid management segments. Revenue for FY25 rose 8% year-over-year to €2.15 billion, while adjusted EBITDA margin held steady at 31.2%. Management expects mid-single-digit sales growth in FY26, supported by long-term industry tailwinds including increased biologics production and outsourcing trends. The firm also reaffirmed its 2028 financial targets.